- Home
- MDRR vs SABS Comparison
MDRR vs SABS Comparison
Compare MDRR & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDRR
- SABS
- Stock Information
- Founded
- MDRR 2015
- SABS 2014
- Country
- MDRR United States
- SABS United States
- Employees
- MDRR N/A
- SABS N/A
- Industry
- MDRR Real Estate Investment Trusts
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- MDRR Real Estate
- SABS Health Care
- Exchange
- MDRR Nasdaq
- SABS Nasdaq
- Market Cap
- MDRR 15.8M
- SABS 15.8M
- IPO Year
- MDRR 2018
- SABS N/A
- Fundamental
- Price
- MDRR $12.72
- SABS $2.07
- Analyst Decision
- MDRR
- SABS Strong Buy
- Analyst Count
- MDRR 0
- SABS 5
- Target Price
- MDRR N/A
- SABS $10.00
- AVG Volume (30 Days)
- MDRR 6.1K
- SABS 92.4K
- Earning Date
- MDRR 08-07-2025
- SABS 08-07-2025
- Dividend Yield
- MDRR 2.12%
- SABS N/A
- EPS Growth
- MDRR N/A
- SABS N/A
- EPS
- MDRR N/A
- SABS N/A
- Revenue
- MDRR $9,649,145.00
- SABS $114,698.00
- Revenue This Year
- MDRR N/A
- SABS N/A
- Revenue Next Year
- MDRR N/A
- SABS N/A
- P/E Ratio
- MDRR N/A
- SABS N/A
- Revenue Growth
- MDRR N/A
- SABS N/A
- 52 Week Low
- MDRR $9.55
- SABS $1.00
- 52 Week High
- MDRR $15.00
- SABS $6.60
- Technical
- Relative Strength Index (RSI)
- MDRR 65.03
- SABS 45.94
- Support Level
- MDRR $10.24
- SABS $1.97
- Resistance Level
- MDRR $12.50
- SABS $2.29
- Average True Range (ATR)
- MDRR 0.51
- SABS 0.11
- MACD
- MDRR 0.13
- SABS -0.00
- Stochastic Oscillator
- MDRR 98.94
- SABS 40.00
About MDRR Medalist Diversified REIT Inc.
Medalist Diversified REIT Inc is engaged to acquire, reposition, renovate, lease, and manage income-producing properties with a focus on commercial properties, including flex-industrial and retail properties, multi-family residential properties, and hotel properties. The company operates as a UPREIT and owns properties through its subsidiary, Medalist Diversified Holdings, LP. Its reportable segments were retail center properties, flex center properties, and STNL properties.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.